The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

1. Characterization of lipid components in lipid nanoparticle (LNP) formulations – Application Note AN001928 – an-001928-bt-lipid-components-LNP-an001928-na-en.pdf (SECURED) ...

Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.

Analysts at StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s ...

Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a report issued on Monday, February 24th. HC Wainwright analyst P.

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

Vilobelimab is being developed for various debilitating or life-threatening inflammatory indications, including a Phase 3 trial for pyoderma gangrenosum (PG). Vilobelimab has been granted orphan drug ...

The global microbiology culture market propelled by increasing demand across sectors such as pharmaceuticals, food and ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...